Vascarta Outlines Proposed Mechanistic Link Between VAS-101's (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease

Summary

Vascarta presented preclinical findings connecting VAS-101's vascular and red blood cell effects in sickle cell disease, proposing a mechanistic link between microcirculation improvements and red blood cell sickling kinetics without direct hemoglobin S polymerization inhibition.